Jeffrey Winkler

Dr. Jeffrey Winkler

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
QMQuentin McAfee
Quentin McAfee
ZZZhihui Zhang
Zhihui Zhang
ASArabinda Samanta
Arabinda Samanta
SLSamuel M. Levi
Samuel M. Levi
XMXiao-Hong Ma
Xiao-Hong Ma
RARavi Amaravadi
Ravi Amaravadi
Autophagy is a lysosome-dependent degradative process that protects cancer cells from multiple stresses. In preclinical models, autophagy inhibition with chloroquine (CQ) derivatives augments the efficacy of many anticancer therapies, but CQ has limited activity as a single agent. Clinical trials are underway combining anticancer agents with hydroxychloroquine (HCQ), but concentrations of HCQ required to inhibit autophagy are not consistently achievable in the clinic. We report the synthesis and characterization of bisaminoquinoline autophagy inhibitors that potently inhibit autophagy and impair tumor growth in vivo. The structural motifs that are necessary for improved autophagy inhibition compared with CQ include the presence of two aminoquinoline rings and a triamine linker and C-7 chlorine. The lead compound, Lys01, is a 10-fold more potent autophagy inhibitor than HCQ. Compared with HCQ, Lys05, a water-soluble salt of Lys01, more potently accumulates within and deacidifies the lysosome, resulting in impaired autophagy and tumor growth. At the highest dose administered, some mice develop Paneth cell dysfunction that resembles the intestinal phenotype of mice and humans with genetic defects in the autophagy gene ATG16L1 , providing in vivo evidence that Lys05 targets autophagy. Unlike HCQ, significant single-agent antitumor activity is observed without toxicity in mice treated with lower doses of Lys05, establishing the therapeutic potential of this compound in cancer.

1 February 2019 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
VRVito W. Rebecca
Vito W. Rebecca
MNMichael C. Nicastri
Michael C. Nicastri
CFColin Fennelly
Colin Fennelly
RARavi Amaravadi
Ravi Amaravadi
JBJulie S. Barber-Rotenberg
Julie S. Barber-Rotenberg
RARavi Amaravadi
Ravi Amaravadi
Clinical trials repurposing lysosomotropic chloroquine (CQ) derivatives as autophagy inhibitors in cancer demonstrate encouraging results, but the underlying mechanism of action remains unknown. Here, we report a novel dimeric CQ (DC661) capable of deacidifying the lysosome and inhibiting autophagy significantly better than hydroxychloroquine (HCQ). Using an in situ photoaffinity pulldown strategy, we identified palmitoyl-protein thioesterase 1 (PPT1) as a molecular target shared across monomeric and dimeric CQ derivatives. HCQ and Lys05 also bound to and inhibited PPT1 activity, but only DC661 maintained activity in acidic media. Knockout of PPT1 in cancer cells using CRISPR/Cas9 editing abrogates autophagy modulation and cytotoxicity of CQ derivatives, and results in significant impairment of tumor growth similar to that observed with DC661. Elevated expression of PPT1 in tumors correlates with poor survival in patients in a variety of cancers. Thus, PPT1 represents a new target in cancer that can be inhibited with CQ derivatives. Significance: This study identifies PPT1 as the previously unknown lysosomal molecular target of monomeric and dimeric CQ derivatives. Genetic suppression of PPT1 impairs tumor growth, and PPT1 levels are elevated in cancer and associated with poor survival. These findings provide a strong rationale for targeting PPT1 in cancer. This article is highlighted in the In This Issue feature, p. 151

1 November 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
VRVito W. Rebecca
Vito W. Rebecca
MNMichael C. Nicastri
Michael C. Nicastri
NMNoel McLaughlin
Noel McLaughlin
CFColin Fennelly
Colin Fennelly
QMQuentin McAfee
Quentin McAfee
RARavi Amaravadi
Ravi Amaravadi
Lysosomes serve dual roles in cancer metabolism, executing catabolic programs (i.e., autophagy and macropinocytosis) while promoting mTORC1-dependent anabolism. Antimalarial compounds such as chloroquine or quinacrine have been used as lysosomal inhibitors, but fail to inhibit mTOR signaling. Further, the molecular target of these agents has not been identified. We report a screen of novel dimeric antimalarials that identifies dimeric quinacrines (DQ) as potent anticancer compounds, which concurrently inhibit mTOR and autophagy. Central nitrogen methylation of the DQ linker enhances lysosomal localization and potency. An in situ photoaffinity pulldown identified palmitoyl-protein thioesterase 1 (PPT1) as the molecular target of DQ661. PPT1 inhibition concurrently impairs mTOR and lysosomal catabolism through the rapid accumulation of palmitoylated proteins. DQ661 inhibits the in vivo tumor growth of melanoma, pancreatic cancer, and colorectal cancer mouse models and can be safely combined with chemotherapy. Thus, lysosome-directed PPT1 inhibitors represent a new approach to concurrently targeting mTORC1 and lysosomal catabolism in cancer. Significance: This study identifies chemical features of dimeric compounds that increase their lysosomal specificity, and a new molecular target for these compounds, reclassifying these compounds as targeted therapies. Targeting PPT1 blocks mTOR signaling in a manner distinct from catalytic inhibitors, while concurrently inhibiting autophagy, thereby providing a new strategy for cancer therapy. Cancer Discov; 7(11); 1266–83. ©2017 AACR. See related commentary by Towers and Thorburn, p. 1218. This article is highlighted in the In This Issue feature, p. 1201

31 July 2002 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JWJeffrey Winkler
Jeffrey Winkler
MRMeagan B. Rouse
Meagan B. Rouse
MGMichael F. Greaney
Michael F. Greaney
SHSean J. Harrison
Sean J. Harrison
YJYoon T. Jeon
Yoon T. Jeon

14 September 2012 in Autophagy
Verified
Journal Article
Open access
PDF file
RARavi Amaravadi
Ravi Amaravadi
JWJeffrey Winkler
Jeffrey Winkler
Lys05 is a previously undescribed dimeric chloroquine which more potently accumulates in the lysosome and blocks autophagy compared with HCQ. Lys05 produced more potent antitumor activity as a single agent both in vitro and in vivo in multiple human cancer cell lines and xenograft models compared with HCQ. Initial structure-activity relationship studies demonstrated that the increased activity associated with Lys05 was due to the bivalent aminoquinoline rings, C7-Chlorine, and a short triamine linker. While lower doses of Lys05 were well tolerated and associated with antitumor activity, at the highest dose tested, Lys05 produced Paneth cell dysfunction and intestinal toxicity, similar to what can be observed in mice and humans with genetic defects in the autophagy gene ATG16L1. Lys05 is therefore a new lysosomal autophagy inhibitor that has potential to be developed further into a drug for cancer and other medical applications.

20 January 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AAAdegoke O. Adeniji
Adegoke O. Adeniji
BTBarry M. Twenter
Barry M. Twenter
MBMichael C. Byrns
Michael C. Byrns
YJYi Jin
Yi Jin
MCMo Chen
Mo Chen
Trevor PenningTrevor Penning
Trevor Penning